Clinical Trials Logo

Filter by:
NCT ID: NCT05713240 Not yet recruiting - Clinical trials for Sudden Cardiac Death

REgiStry in Chinese yoUng pEople With Sudden Cardiac Death

RESCUE-SCD
Start date: March 1, 2023
Phase:
Study type: Observational

The number of sudden cardiac death is up to 540,000 every year in China. Inherited cardiovascular disease is a common cause of sudden cardiac death in young people, and diseases often have the characteristics of family aggregation, so it has a huge psychological and economic burden on family members. Studying the etiology of sudden cardiac death from the molecular level under the model of precision medicine is helpful for screening patients and their relatives so as to further diagnosis, treatment and management, which has important clinical and social significance.

NCT ID: NCT05713110 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Start date: February 13, 2023
Phase: Phase 2
Study type: Interventional

A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase (phase IIb).

NCT ID: NCT05712902 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation

Start date: July 19, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of DZD9008 in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy

NCT ID: NCT05712785 Recruiting - Urinary Calculi Clinical Trials

Shuotongo Ureteroscopy for Upper Urinary Tract Stones

SFUUTS
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to use the Shuotong ureteroscopy for surgical treatment of patients with upper urinary tract stones, taking advantage of the fact that the Shuotong mirror can be used for simultaneous lithotripsy and stone removal, thus maximizing the discharge of stones from the body and improving the stone removal rate.

NCT ID: NCT05712304 Recruiting - Adenoma Miss Rate Clinical Trials

Impact of SE of the Proximal Colon on the AMR

Start date: February 15, 2023
Phase: N/A
Study type: Interventional

.Studies have demonstrated that the second examination of the proximal colon can significantly increase the proximal ADR.This study aimed to determine the impact of second examination of the proximal colon on AMR compared to conventional examination.Consecutive patients aged 40-75years undergoing colonoscopy for screening.Tandem withdrawal was used in the proximal colon.Patients were randomly assigned to either the second examination(SE) or the conventional examination(CE) group.The primary outcome measure was proximal AMR,defined as the number of proximal adenomas detected in the second pass(CE group)or the third pass(SE group)divided by the total number of proximal adenomas detected during the tandem colonoscopy.

NCT ID: NCT05712200 Recruiting - Clinical trials for Atrial Fibrillation (AF)

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

LILAC-TIMI 76
Start date: December 27, 2022
Phase: Phase 3
Study type: Interventional

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

NCT ID: NCT05712083 Recruiting - Multiple Myeloma Clinical Trials

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Start date: January 30, 2023
Phase: Phase 2
Study type: Interventional

Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

NCT ID: NCT05712018 Completed - Adverse Effect Clinical Trials

Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine

Start date: October 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of different 6% hydroxyethyl starch (130/0.4) coload volumes on the 90% effective dose of norepinephrine infusion prophylaxis for hypotension during spinal anesthesia for cesarean section.

NCT ID: NCT05711810 Completed - Renal Dialysis Clinical Trials

Medicine-induced Cardiac Hemodialysis on COVID-19

Start date: January 2, 2023
Phase: Phase 4
Study type: Interventional

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

NCT ID: NCT05711797 Recruiting - Influenza, Human Clinical Trials

Pharmacokinetic Characteristics of Subjects With Hepatic Insufficiency and Healthy Subjects

Start date: November 2, 2022
Phase: Phase 1
Study type: Interventional

The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with healthy subjects matched by age, weight, and sex. And to evaluate the the safety and tolerability of ZX-7101A by a single oral dose in subjects. The main questions it aims to answer are: - Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver dysfunction and healthy subjects with normal liver function matched for age, weight, and sex. - To evaluate the safety and tolerability of ZX-7101A by a single oral dose in subjects.